Literature DB >> 33402731

Silencing long noncoding RNA colon cancer-associated transcript-1 upregulates microRNA-34a-5p to promote proliferation and differentiation of osteoblasts in osteoporosis.

Fangke Hu1, Chengying Jiang2, Guoyun Bu1, Yiru Fu2, Yanfang Yu3.   

Abstract

Long noncoding RNAs (lncRNAs) have been revealed to be related to multiple physiological and pathology processes such as development, carcinogenesis, and osteogenesis. It is reported that lncRNAs might exert function in osteoblast differentiation and bone formation. Here, we determined this study to clarify whether lncRNA CCAT1 could regulate osteoblast proliferation and differentiation in ovariectomized rats with osteoporosis. The osteoporosis models were established by bilateral ovariectomy and treated with CCAT1 siRNAs to discuss the effect of CCAT1 on pathological changes and osteocyte apoptosis in ovariectomized rats with osteoporosis. The osteoblasts from ovariectomized rats were cultured in vitro, which were then treated with CCAT1 siRNAs to explore the role of CCAT1 in osteoblast proliferation and differentiation. Moreover, the relationships among CCAT1, miR-34a-5p, and SMURF2 were confirmed. CCAT1 and SMURF2 were amplified while miR-34a-5p expression was inhibited in bone tissues and osteoblasts of ovariectomized rats with osteoporosis. Inhibited CCAT1 improved pathology and restricted osteocyte apoptosis of bone tissues in ovariectomized rats with osteoporosis in vivo, and also enhanced differentiation, mineralization abilities, and proliferation, and suppressed apoptosis of osteoblasts from ovariectomized rats in vitro through upregulating miR-34a-5p expression. LncRNA CCAT1 could competitively bind with miR-34a-5p to prevent the degradation of its target gene SMURF2. Results of this research suggested that the CCAT1 inhibits the proliferation and differentiation of osteoblasts in rats with osteoporosis by binding to miR-34a-5p, providing novel biomarkers for osteoporosis treatment.
© 2021. The Author(s), under exclusive licence to Springer Nature America, Inc. part of Springer Nature.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33402731     DOI: 10.1038/s41417-020-00264-7

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.854


  2 in total

1.  LncRNA CCAT1 negatively regulates miR-181a-5p to promote endometrial carcinoma cell proliferation and migration.

Authors:  Jing Yu; Lijuan Jiang; Yutao Gao; Qijian Sun; Beibei Liu; Yong Hu; Xuesong Han
Journal:  Exp Ther Med       Date:  2019-03-20       Impact factor: 2.447

2.  Human amniotic epithelial cells regulate osteoblast differentiation through the secretion of TGFβ1 and microRNA-34a-5p.

Authors:  Guiling Wang; Feng Zhao; Di Yang; Jing Wang; Lihong Qiu; Xining Pang
Journal:  Int J Mol Med       Date:  2017-11-17       Impact factor: 4.101

  2 in total
  5 in total

1.  Comprehensive analysis of lncRNA-miRNA-mRNA networks during osteogenic differentiation of bone marrow mesenchymal stem cells.

Authors:  Jialin Liu; Yuan Yao; Jinyong Huang; Hao Sun; Yixuan Pu; Mengting Tian; Meijie Zheng; Huiyu He; Zheng Li
Journal:  BMC Genomics       Date:  2022-06-07       Impact factor: 4.547

Review 2.  The management of bone defect using long non-coding RNA as a potential biomarker for regulating the osteogenic differentiation process.

Authors:  Jia-Lin Liu; Yan-Shi Liu; Mei-Jie Zheng; Hui-Yu He
Journal:  Mol Biol Rep       Date:  2022-01-01       Impact factor: 2.316

Review 3.  Oxidative Stress and Inflammation in Cardiovascular Diseases and Cancer: Role of Non-coding RNAs.

Authors:  Pieterjan Ginckels; Paul Holvoet
Journal:  Yale J Biol Med       Date:  2022-03-31

Review 4.  NEDD4 E3 Ligases: Functions and Mechanisms in Bone and Tooth.

Authors:  Ke Xu; Yanhao Chu; Qin Liu; Wenguo Fan; Hongwen He; Fang Huang
Journal:  Int J Mol Sci       Date:  2022-09-01       Impact factor: 6.208

Review 5.  Effects of miRNAs, lncRNAs and circRNAs on osteoporosis as regulatory factors of bone homeostasis (Review).

Authors:  Zhichao Li; Haipeng Xue; Guoqing Tan; Zhanwang Xu
Journal:  Mol Med Rep       Date:  2021-09-10       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.